etodolac has been researched along with guaifenesin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doman, TN; McGovern, SL; Seidler, J; Shoichet, BK | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ara, N; Ichikawa, T; Iijima, K; Ishihara, K; Iwabuchi, T; Kamata, Y; Koike, T; Shimosegawa, T; Shinkai, H | 1 |
1 review(s) available for etodolac and guaifenesin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for etodolac and guaifenesin
| Article | Year |
|---|---|
Increased gastric mucus secretion alleviates non-steroidal anti-inflammatory drug-induced abdominal pain.
Topics: Abdominal Pain; Adult; Anti-Inflammatory Agents, Non-Steroidal; Dinoprostone; Etodolac; Gastric Mucosa; Humans; Male; Mucus; Naproxen; Stomach; Young Adult | 2013 |
1 other study(ies) available for etodolac and guaifenesin
| Article | Year |
|---|---|
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
Topics: Antifungal Agents; beta-Lactamase Inhibitors; Chemical Phenomena; Chemistry, Physical; Chymotrypsin; Enzyme Inhibitors; Kinetics; Light; Malate Dehydrogenase; Models, Molecular; Molecular Conformation; Scattering, Radiation; Structure-Activity Relationship | 2003 |